Eculizumab
Soliris (eculizumab) is a monoclonal antibody medication that works by inhibiting the complement system, specifically targeting the C5 protein to prevent the formation of the terminal complement complex. It is primarily prescribed for rare blood disorders and certain autoimmune conditions where abnormal complement activation plays a key role in disease progression.
Soliris is a complement inhibitor used to treat rare blood disorders and certain autoimmune conditions by blocking abnormal complement activation.
Key facts at a glance
- RxNorm
- 680973
- Generic
- Soliris
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Soliris is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive.
Soliris is a monoclonal antibody that specifically binds to the C5 complement protein, preventing its cleavage into pro-inflammatory fragments and blocking the formation of the membrane attack complex (MAC). This inhibits the terminal pathway of complement activation, reducing hemolysis in PNH and aHUS, and decreasing immune-mediated damage in gMG and NMOSD.
Soliris carries a boxed warning for increased risk of serious meningococcal infections; patients must receive meningococcal vaccines before starting treatment and be monitored for signs of infection. It is administered as an intravenous infusion, typically every 7-14 days depending on the indication. Treatment should only be initiated by healthcare providers experienced in managing the specific conditions Soliris treats.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy